Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Tate & Lyle pleased by volume momentum

(Sharecast News) - Tate&Lyle reported an increase in operating profits at the start of its 2025 fiscal year. That was despite the drag on the topline at its Food & Beverage solutions unit, although revenue growth at Sucralose was described as "good".

All in all, in a trading statement for the three months ending on 30 June the food ingredients maker said that group performance had met management's expectations.

It's encouraging to see volume momentum across the business, and we continue to expect volume growth to accelerate as the 2025 financial year progresses," the company's chief executive officer, Nick Hampton, said.

"Planning for the integration of Tate & Lyle and CP Kelco is progressing well with both organisations excited about the opportunity to deliver significantly greater value for customers and the growth potential of the combined business. We look forward to the future with confidence."

On 20 June the company had announced its intention to acquire CP Kelco, the pectin provider, for $1.8bn (£1.4bn).

Ahead of its AGM, the company also reiterated guidance for a dip in revenues on a constant currency basis while earnings before interest, taxes, depreciation and amortisation were seen rising by 4-7%.

As at 24 July, the company had repurchased 6.7m of its own shares at a cost of £42m as part of the £215m share buyback programme unveiled on 20 June.

Shares in Tate&Lyle were adding 0.86% to 648.50p as of 1510 BST.

Share this article

Related Sharecast Articles

Smith & Nephew appoints Ajay Dhankhar as chief corporate development & strategy officer
(Sharecast News) - Medical technology company Smith & Nephew said on Monday that it has appointed Ajay Dhankhar as chief corporate development & strategy officer with immediate effect.
Oxford Biomedica acquires last 10pc stake in US subsidiary
(Sharecast News) - Oxford Biomedica said on Monday it has acquired the remaining 10% stake in its US subsidiary, OXB US, from Q32 Bio, bringing its ownership of the business to 100% as previously planned.
PPHE acquiring prime London site for hotel development
(Sharecast News) - PPHE Hotel Group has announced the acquisition of a prime development site near the City of London, where it plans to build its first Radisson RED select service hotel in the capital.
Norcros to end tile production in South Africa
(Sharecast News) - Norcros announced on Monday that it will shut down manufacturing at Johnson Tiles South Africa at the end of June, following the conclusion of a strategic review.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.